Search results for "Estrogen"

showing 10 items of 530 documents

Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells.

2006

Objective: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthase, is a novel cardiovascular risk factor produced by endothelial cells. ADMA levels are mainly regulated by the activity of dimethylarginine dimethylaminohydrolases (DDAH). Endothelial release of ADMA is increased in the presence of oxidized LDL cholesterol (oxLDL), whereas estrogens stimulate NO production by endothelial cells by increasing both expression and activity of NO synthase and by reducing ADMA levels. Thus, the aim of the present study was to evaluate the estradiol effects on the DDAH/ADMA/NO pathway in cultured human umbilical vein endothelial cells (HUVEC) exposed to LDL. Methods…

Adultmedicine.medical_specialtyEndotheliumPhysiologymedicine.drug_classImmunoblottingGene ExpressionBiologyArginineNitric OxideUmbilical veinNitric oxideAmidohydrolaseschemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineElectrochemistryHumansRNA MessengerCells CulturedChromatography High Pressure LiquidAnalysis of VarianceEstradiolReverse Transcriptase Polymerase Chain ReactionEndothelial CellsEndothelial stem cellNitric oxide synthaseLipoproteins LDLmedicine.anatomical_structureEndocrinologychemistryCell cultureEstrogenbiology.proteinEndothelium VascularNitric Oxide SynthaseCardiology and Cardiovascular MedicineAsymmetric dimethylarginineCardiovascular research
researchProduct

Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losarta…

2009

Abstract The incidence of cardiovascular diseases in premenopausal women is lower than in men or postmenopausal women. This study reports the discovery of a low grade of systemic inflammation, including monocyte adhesion to arterial endothelium, elicited by menopause or estrogen depletion. Chronic treatment with low dose of 17-β-estradiol or inhibition of the renin-angiotensin system reduced this inflammation. Using an in vitro flow chamber system with human arterial and venous endothelial cells, we found that leukocytes from healthy postmenopausal women were more adhesive to the arterial endothelium than those from premenopausal women regardless of the stimulus used on endothelial cells. I…

Adultmedicine.medical_specialtyEndotheliummedicine.drug_classOvariectomyImmunologyInflammationSystemic inflammationLosartanRats Sprague-DawleyInternal medicinemedicineCell AdhesionLeukocytesImmunology and AllergyAnimalsHumansCells CulturedInflammationCell adhesion moleculebusiness.industryEndothelial CellsEstrogensBenzazepinesMiddle Agedmedicine.diseaseRatsMenopausemedicine.anatomical_structureEndocrinologyLosartanEstrogenCase-Control StudiesOvariectomized ratFemaleEndothelium Vascularmedicine.symptomChemokinesMenopausebusinessAngiotensin II Type 1 Receptor BlockersCell Adhesion Moleculesmedicine.drugJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Uterine fibroids risk and history of selected medical conditions linked with female hormones

2004

To understand the role of several medical conditions on the risk of uterine fibroids, we analysed the findings of a large case-control study. Cases were 843 women aged 54 or less (median age 43 years, range 21-54) with histologically confirmed uterine fibroids, whose clinical diagnosis dated back no more than 2 years. Indications for surgery were recurrent menorrhagia or ultrasound evidence of fibroids larger than 10 cm in diameter. Controls were 1557 women aged 54 years or less of comparable quinquennia of age (median age 43 years, range 21-54) who had not undergone hysterectomy and were admitted for acute, non-gynecologic, non-hormonal, non-neoplastic conditions to a network of hospitals …

Adultmedicine.medical_specialtyFibroidsUterine fibroidsEpidemiologymedicine.medical_treatmentEpidemiologyMedicineHumansMedical historyRisk factorMedical History TakingGynecologyHysterectomyLeiomyomabusiness.industryCase-control studyEstrogensOdds ratioMiddle Agedmedicine.diseaseEstrogenfemale genital diseases and pregnancy complicationsLeiomyomaItalyCase-Control StudiesEpidemiology; Fibroids; Medical historyMedical historyFemaleCase-Control StudiebusinessHuman
researchProduct

Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial

2013

Abstract Background Both oral contraceptive pills (OCPs) and estradiol (E2) valerate have been used to schedule gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles and, consequently, laboratory activities. However, there are no studies comparing treatment outcomes directly between these two pretreatment methods. This randomized controlled trial was aimed at finding differences in ongoing pregnancy rates between GnRH antagonist IVF cycles scheduled with OCPs or E2 valerate. Methods Between January and May 2012, one hundred consecutive patients (nonobese, regularly cycling women 18–38 years with normal day 3 hormone levels and <3 previous IVF/ICSI attempts)…

Adultmedicine.medical_specialtyPregnancy Ratemedia_common.quotation_subjectPopulationPhysiologyFertilization in VitroCycle schedulingReproductive technologyGonadotropin-releasing hormoneValerateContraceptives Oral Hormonallaw.inventionGonadotropin-Releasing HormoneEndocrinologyRandomized controlled trialPregnancylawInternal medicineGnRH antagonistHumansMedicineeducationMenstrual CycleMenstrual cyclemedia_commonchemistry.chemical_classificationeducation.field_of_studyEstradiolOral contraceptivesbusiness.industryResearchEstradiol valerateEstrogen pretreatmentObstetrics and GynecologyPregnancy rateEndocrinologychemistryReproductive MedicineIVFFemalebusinessmedicine.drugDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

Modulation of oestrogen excretion profiles by adjuvant chemotherapy in pre- and postmenopausal breast cancer.

1985

Modulation of steroid status by conventional chemotherapy was studied in 31 breast cancer patients receiving CMF and in 31 age-matched breast cancer patients without any therapy, taken as controls. This was achieved through the study of oestrogen excretion profiles using previously identified parameters and referring not only to classical but also to the “other”, namely catechol and unusual, oestrogen metabolites. After CMF treatment the premenopausal patients exhibit a modified excretion pattern, mainly concerning a marked and significant reduction of classical oestrogens, as shown by pattern indices. Because there is evidence that oestriol metabolism is not markedly affected by CMF treatm…

Adultmedicine.medical_specialtyTime FactorschlormethineAdjuvant chemotherapymedicine.medical_treatmentBreast NeoplasmsBiochemistryestriolGas Chromatography-Mass SpectrometrySteroidExcretionEndocrinologyBreast cancerInternal medicineestradiolAntineoplastic Combined Chemotherapy ProtocolsmedicineestrogenHumansStage (cooking)CyclophosphamideChromatography High Pressure LiquidAgedbusiness.industryEstrogensMetabolismMiddle Agedmedicine.diseaseestroneEstrogens CatecholEndocrinologyMethotrexateMetabolic rateAdrenal CortexFemaleFluorouracilMenopausebusinessAfter treatmentJournal of steroid biochemistry
researchProduct

Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endo…

2003

OBJECTIVE: The present study aims at demonstrating the equivalence of the 28-day and 3-month formulations of triptorelin SR (sustained release) in terms of percentage of patients achieving castration levels of estradiol (<==50 pg/mL) 84 days after treatment initiation. DESIGN: A phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis. SETTING: Academic hospitals. PATIENT(S): Seventy-two women with endometriosis. were treated with a single intramuscular injection of 3-month triptorelin SR, and 74 patients were treated with one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months. INTERVENTION(S): As pa…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classChemistry PharmaceuticalPopulationEndometriosisUrologyEndometriosisInjections IntramuscularDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawRecurrenceestrogenmedicineHumanseducationGynecologyeducation.field_of_studyTriptorelin PamoateEstradiolDecapeptylbusiness.industryendometriositriptorelinObstetrics and GynecologyMedical castrationLuteinizing Hormonemedicine.diseaseTriptorelinLuteolytic AgentsCastrationReproductive MedicinechemistryEstrogenPharmacodynamicsFemaleFollicle Stimulating HormoneIntramuscular injectionbusinessmedicine.drugFertility and sterility
researchProduct

Characteristics of urinary luteinizing hormone (LH) during the induction of LH surges of different magnitude in blood

1995

Urinary luteinizing hormone (LH) testing has been proposed as a reliable method for the prediction of ovulation but its accuracy has been challenged by some studies. To check how accurately the oscillations of urinary LH reflected the plasma changes, surges of LH of different magnitude and duration were artificially induced in plasma and the hormone was measured simultaneously in urine. Post-menopausal women (n = 16) were stimulated during 1 week with a combination of transdermal oestradiol (400 micrograms) and i.m. progesterone (25 mg on day 4, 50 mg on day 5) to obtain an LH discharge comparable with the pre-ovulatory LH peak. A short and moderate peak of LH was induced by the i.v. inject…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classmedia_common.quotation_subjectRadioimmunoassayGonadotropin-releasing hormoneUrineBuserelinSensitivity and SpecificityGonadotropin-Releasing HormoneAndrologyInternal medicinemedicineHumansOvulationProgesteronemedia_commonOvulation DetectionEstradiolChemistryEstrogen Replacement TherapyRehabilitationReproducibility of ResultsObstetrics and GynecologyLuteinizing HormoneMiddle Agedmedicine.diseaseBuserelinMenopauseEndocrinologyReproductive MedicineFemaleMenopauseGonadotropinLuteinizing hormonemedicine.drugHormoneHuman Reproduction
researchProduct

Variations in central corneal thickness during the menstrual cycle in women.

2007

PURPOSE: We report changes in the central corneal thickness during various phases of the menstrual cycle. METHODS: We recruited 16 healthy women of reproductive age and measured the central corneal thickness at 3 points in their menstrual cycle, beginning on days 1 to 3 and again at ovulation and at the end of the cycle (days 27-32). Ovulation was determined with a test that determines the peak of luteinizing hormone in the urine. RESULTS: We found that the central cornea was thinnest at the beginning of the cycle (mean = 536 microm). Corneal thickness increased at ovulation (mean = 549 microm) and at the end of the cycle (mean = 559 microm). The difference in corneal thickness was statisti…

Adultmedicine.medical_specialtyVisual acuitymedia_common.quotation_subjectVisual AcuityReproductive ageCorneal thickness menstrual cycleCorneaReference ValuesMedicineHumansBody Weights and MeasuresOvulationMenstrual cycleMenstrual Cyclemedia_commonUltrasonographySettore MED/30 - Malattie Apparato Visivobusiness.industryObstetricsFollow up studiesEstrogensSettore MED/40 - Ginecologia E OstetriciaOphthalmologyReference valuesFemalesense organsUltrasonographymedicine.symptombusinessFollow-Up StudiesCornea
researchProduct

Uterine effects of clomiphene citrate in women with polycystic ovary syndrome: a prospective controlled study

2006

Background Previous data on the efficacy of clomiphene citrate, the most commonly used drug for treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS), have shown a discrepancy between ovulation and pregnancy rates. In the present subanalysis (of a larger previously published randomized controlled trial), the effect of clomiphene citrate on several ultrasonographic markers of uterine receptivity in PCOS patients who ovulated under treatment was studied. Methods Thirty-three PCOS women who ovulated under 150 mg daily clomiphene citrate and 33 healthy controls were studied. Uterine, subendometrial and endometrial blood flows, endometrial thickness and pattern were …

Adultmedicine.medical_specialtymedia_common.quotation_subjectEarly Pregnancy LossUterusanovulation; clomiphene citrate; Doppler; PCOS; velocimetryBiologyClomiphenelaw.inventionAnovulationRandomized controlled trialPregnancyReference ValueslawClomifeneclomiphene citratemedicinePCOSHumansOvulationUltrasonographymedia_commonGynecologyPregnancyvelocimetryObstetricsRehabilitationEstrogen AntagonistsPregnancy OutcomeDopplerObstetrics and GynecologyGenitalia Femalemedicine.diseasePolycystic ovaryTreatment Outcomemedicine.anatomical_structureReproductive Medicinepolycystic ovary syndromeanovulationFemalemedicine.drug
researchProduct

The effect of hormonal status on the expression of estrogen and progesterone receptor in vaginal wall and periurethral tissue in urogynecological pat…

2009

Abstract Objective Our objective was to study the expression of estrogen receptor (ER) isoforms ER alpha (α) and ER beta (β) and of progesterone receptor (PR) in the vaginal wall and in periurethral tissue of women who underwent urogynecological surgical treatment with reference to estrogen status. Study design The study included 89 patients undergoing vaginal surgery for urogynecological conditions. Patients’ history and clinical data including estrogen status and body mass index (BMI) were evaluated. Biopsies from the vaginal wall and from periurethral tissue were obtained during surgery. The expression of ER α and β and of PR in vaginal wall and periurethral tissue was measured by RT-PCR…

Adultmedicine.medical_specialtymedicine.drug_classReceptor expressionEstrogen receptorUrethraInternal medicineProgesterone receptormedicineHumansEstrogen receptor betaAgedAged 80 and overReverse Transcriptase Polymerase Chain Reactionbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyEstrogensMiddle AgedEndocrinologymedicine.anatomical_structureReceptors EstrogenReproductive MedicineEstrogenVaginaVaginaFemaleReceptors ProgesteronebusinessProgestinEstrogen receptor alphaEuropean Journal of Obstetrics &amp; Gynecology and Reproductive Biology
researchProduct